European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Kroese, Tiuri EBronzwaer, Sebastiaan
van Rossum, Peter S N
Schoppman, Sebastian F
Deseyne, Pieter R A J
van Cutsem, Eric
Haustermans, Karin
Nafteux, Philippe
Thomas, Melissa
Obermannova, Radka
Mortensen, Hanna R
Nordsmark, Marianne
Pfeiffer, Per
Elme, Anneli
Adenis, Antoine
Piessen, Guillaume
Bruns, Christiane J
Lordick, Florian
Gockel, Ines
Moehler, Markus
Gani, Cihan
Liakakos, Theodore
Reynolds, John V
Morganti, Alessio G
Rosati, Riccardo
Castoro, Carlo
Cellini, Francesco
D'Ugo, Domenico
Roviello, Franco
Bencivenga, Maria
de Manzoni, Giovanni
van Berge Henegouwen, Mark I
Hulshoff, Maarten C C M
van Dieren, Jolanda
Vollebergh, Marieke
van Sandick, Johanna W
Jeene, Paul
Muijs, Christel
Slingerland, Marije
Voncken, Francine E M
Hartgrink, Henk
Creemers, Geert-Jan
van der Sangen, Maurice J C
Nieuwenhuijzen, Grard A P
Berbee, Maaike
Verheij, Marcel
Wijnhoven, Bas
Beerepoot, Laurens V
Mohammad, Nadia Haj
Mook, Stella
Ruurda, Jelle P
Kolodziejczyk, Piotr
Polkowski, Wojciech P
Wyrwicz, Lucjan
Alsina, Maria
Tabernero, Josep
Pera, Manuel
Kanonnikoff, Tania F
Cervantes, Andrés
Nilsson, Magnus
Monig, Stefan
Wagner, Anna D
Guckenberger, Matthias
Griffiths, Ewen A
Smyth, Elizabeth
Hanna, George B
Markar, Sheraz
Chaudry, M Asif
Hawkins, Maria A
Cheong, Edward
van Laarhoven, Hanneke W M
van Hillegersberg, Richard
Publication date
2024-04-16
Metadata
Show full item recordAbstract
Moderate to high quality of evidence was found (i.e. 1 randomized and 4 non-randomized phase II trials) resulting in moderate recommendations. OMD is considered in esophagogastric cancer patients with 1 organ with ≤ 3 metastases or 1 involved extra-regional lymph node station. In addition, OMD continues to be considered in patients with OMD without progression in number of metastases after systemic therapy. 18F-FDG PET/CT imaging is recommended for baseline staging and for restaging after systemic therapy when local treatment is considered. For patients with synchronous OMD or metachronous OMD and a DFI ≤ 2 years, recommended treatment consists of systemic therapy followed by restaging to assess suitability for local treatment. For patients with metachronous OMD and DFI > 2 years, upfront local treatment is additionally recommended.Citation
Kroese TE, Bronzwaer S, van Rossum PSN, Schoppman SF, Deseyne PRAJ, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen HR, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns CJ, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds JV, Morganti AG, Rosati R, Castoro C, Cellini F, D'Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen MI, Hulshoff MCCM, van Dieren J, Vollebergh M, van Sandick JW, Jeene P, Muijs C, Slingerland M, Voncken FEM, Hartgrink H, Creemers GJ, van der Sangen MJC, Nieuwenhuijzen GAP, Berbee M, Verheij M, Wijnhoven B, Beerepoot LV, Mohammad NH, Mook S, Ruurda JP, Kolodziejczyk P, Polkowski WP, Wyrwicz L, Alsina M, Tabernero J, Pera M, Kanonnikoff TF, Cervantes A, Nilsson M, Monig S, Wagner AD, Guckenberger M, Griffiths EA, Smyth E, Hanna GB, Markar S, Chaudry MA, Hawkins MA, Cheong E, van Laarhoven HWM, van Hillegersberg R; OMEC collaborators. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer. 2024 Jun;204:114062. doi: 10.1016/j.ejca.2024.114062. Epub 2024 Apr 16.Type
ArticleOther
Additional Links
https://www.sciencedirect.com/journal/european-journal-of-cancerPMID
38678762Journal
European Journal of CancerPublisher
Elsevier Scienceae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2024.114062